EPISODE · Jul 1, 2026 · 22 MIN
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
from BioSpace · host BioSpace
The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and IPOs. Plus, a top medical journal this week retracted a pivotal study for Amgen’s rare disease drug Tavneos, which has been in the FDA’s crosshairs since January.
Embed this episode
NOW PLAYING
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
0:00
22:54
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BioSpace?
This episode is 22 minutes long.
When was this BioSpace episode published?
This episode was published on July 1, 2026.
Can I download this BioSpace episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!